Introduction:Retroviral replicating vectors (RRVs) has been proved as an excellent gene therapy vector to achieve efficient gene transduction. To date, more than 499 clinical trials have been carried out using lentivirus vectors for gene delivery and promising gene therapy outcomes have been achieved in a variety of diseases, mostly in cancer. Today, a dual-vector prodrug activator gene therapy has been designed by one research team at the University of Miami to use two different RRVs carrying different prodrug activator genes, which displays synergistic cytocidal effects on different cancer models and indicates the potential utility of dual-vector gene therapy in the future.
On September 29th, the result was published in the journal Cancer Gene Therapy by ” Dual-vector prodrug activator gene therapy using retroviral replicating vectors”. The study reveals a possible combinatorial effect of prodrug activator genes delivered by two different RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV) on human hepatocellular carcinoma Hep3B cells.
“We are outfitting a virus with a suicide gene,” said Kasahara, a Sylvester member. “It forces cancer cells to make an enzyme that converts a non-toxic compound into an active cancer drug, generating that drug right inside the cancer cell itself.”
Vectors used in gene therapy clinical trials. The Journal of Gene Medicine Online Library.[Online] Updated Nov 2017. http://www.abedia.com/wiley/vectors.php
Dual-vector prodrug activator gene therapy using retroviral replicating vectors